Risk of Cerebrovascular Events Among Childhood and Adolescent Patients Receiving Cranial Radiation Therapy: A Pediatric Normal Tissue Effects in the Clinic Normal Tissue Outcomes Comprehensive Review.


Journal

International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616

Informations de publication

Date de publication:
01 Sep 2022
Historique:
received: 02 03 2022
revised: 19 05 2022
accepted: 21 06 2022
entrez: 3 9 2022
pubmed: 4 9 2022
medline: 4 9 2022
Statut: aheadofprint

Résumé

Radiation-induced cerebrovascular toxicity is a well-documented sequelae that can be both life-altering and potentially fatal. We performed a meta-analysis of the relevant literature to create practical models for predicting the risk of cerebral vasculopathy after cranial irradiation. A literature search was performed for studies reporting pediatric radiation therapy (RT) associated cerebral vasculopathy. When available, we used individual patient RT doses delivered to the Circle of Willis (CW) or optic chiasm (as a surrogate), as reported or digitized from original publications, to formulate a dose-response. A logistic fit and a Normal Tissue Complication Probability (NTCP) model was developed to predict future risk of cerebrovascular toxicity and stroke, respectively. This NTCP risk was assessed as a function of prescribed dose. The search identified 766 abstracts, 5 of which were used for modeling. We identified 101 of 3989 pediatric patients who experienced at least one cerebrovascular toxicity: transient ischemic attack, stroke, moyamoya, or arteriopathy. For a range of shorter follow-ups, as specified in the original publications (approximate attained ages of 17 years), our logistic fit model predicted the incidence of any cerebrovascular toxicity as a function of dose to the CW, or surrogate structure: 0.2% at 30 Gy, 1.3% at 45 Gy, and 4.4% at 54 Gy. At an attained age of 35 years, our NTCP model predicted a stroke incidence of 0.9% to 1.3%, 1.8% to 2.7%, and 2.8% to 4.1%, respectively at prescribed doses of 30 Gy, 45 Gy, and 54 Gy (compared with a baseline risk of 0.2%-0.3%). At an attained age of 45 years, the predicted incidence of stroke was 2.1% to 4.2%, 4.5% to 8.6%, and 6.7% to 13.0%, respectively at prescribed doses of 30 Gy, 45 Gy, and 54 Gy (compared with a baseline risk of 0.5%-1.0%). Risk of cerebrovascular toxicity continues to increase with longer follow-up. NTCP stroke predictions are very sensitive to model variables (baseline stroke risk and proportional stroke hazard), both of which found in the literature may be systematically erring on minimization of true risk. We hope this information will assist practitioners in counseling, screening, surveilling, and facilitating risk reduction of RT-related cerebrovascular late effects in this highly sensitive population.

Identifiants

pubmed: 36057476
pii: S0360-3016(22)00643-5
doi: 10.1016/j.ijrobp.2022.06.079
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Jonathan F Waxer (JF)

Department of Radiation Oncology, Southern California Permanente Medical Group, Los Angeles, California.

Kenneth Wong (K)

Radiation Oncology Program, Children's Hospital Los Angeles/Keck School of Medicine of the University of Southern California, Los Angeles, California. Electronic address: kewong@chla.usc.edu.

Arezoo Modiri (A)

Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland.

Anne-Marie Charpentier (AM)

Department of Radiation Oncology, Center Hospitalier de l'Universite de Montreal, Montreal, QC, Canada.

Vitali Moiseenko (V)

Department of Radiation Medicine and Applied Science, University of California San Diego, San Diego, California.

Cécile M Ronckers (CM)

Department of Pediatric Oncology, Princess Maxima Center for Pediatric Oncology, Utretcht, Netherlands.

Phillip J Taddei (PJ)

Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota; Department of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington.

Louis S Constine (LS)

Department of Radiation Oncology and Pediatrics, University of Rochester Medical Center, Rochester, New York.

Grant Sprow (G)

Albert Einstein College of Medicine, Bronx, New York.

Benita Tamrazi (B)

Department of Radiology, Children's Hospital Los Angeles/Keck School of Medicine of the University of Southern California, Los Angeles, California.

Shannon MacDonald (S)

Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

Arthur J Olch (AJ)

Radiation Oncology Program, Children's Hospital Los Angeles/Keck School of Medicine of the University of Southern California, Los Angeles, California.

Classifications MeSH